ifnar

IFN alpha-IFNAR-IN-1 hydrochloride is an inhibitor of the interaction between IFN-α and IFNAR, effectively inhibiting MVA-induced IFN-α responses by BM-pDCs with an IC50 of 2-8 μM.

Deucravacitinib is a highly selective, orally bioavailable, allosteric TYK2 inhibitor for the treatment of autoimmune diseases. It blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain, inhibiting IL-12/23 and type I IFN pathways. It selectively binds to the TYK2 pseudokinase (JH2) domain with an IC50 of 1.0 nM.

Vadimezan (DMXAA) is a vascular disrupting agent, a murine STING agonist, and an inducer of cytokines such as type I IFN. Vadimezan has antitumor activity and induces a rapid cessation of blood flow in tumors without affecting blood flow in normal tissues.

Monalizumab is a novel immune checkpoint inhibitor targeting natural killer cell population 2A (NKG2A). Monalizumab is a humanized monoclonal antibody against NKG2A that induces IFN-γ production, thereby activating natural killer cell function. Monalizumab has antitumor activity and can be used to study neck squamous cell carcinoma (HNSCC).

CP-28888 (CP 28888-27) is an interferon inducer, a lipoamine with antitumor activity.

Cridanimod (10-carboxymethyl-9-acridanone, CMA) is a potent STING agonist that directly binds to STING and triggers a strong antiviral response through the TBK1/IRF3 route.

CCCP (Carbonyl Cyanide m-Chlorophenylhydrazone) is an oxidative phosphorylation (OXPHOS) inhibitor and mitochondrial proton carrier uncoupler. CCCP inhibits the activation of STING and its downstream signaling molecules TBK1 and IRF3.

SM-276001 is a potent, selective agonist of TLR7 and an orally active interferon (IFN) inducer.

Interferon receptor inducer-1 Used in the treatment of a disorder in which the induction of interferon is involved. is an interferon (IFN) receptor inducer.

RO8191 (CDM-3008) (CDM-3008) is an agonist of interferon (IFN) receptor.

Ginsenoside-F3 has immunoenhancing activity by regulating production and gene expression of type 1, type 2 cytokines in murine spleen cells. Ginsenoside-F3 enhances the NF-kappaB DNA binding activity induced by ConA in murine spleen cells (10 μM).

AX-024 hydrochloride (AX-024 HCl) is an cytokine release inhibitor which can strongly inhibit the production of interleukin-6 (IL-6), tumor necrosis factor-α (TNFα), interferon-γ (IFN-γ), IL-10 and IL-17A.

Anifrolumab(MEDI-546) is a potent type I interferon (IFN) receptor antagonist, a human monoclonal antibody that targets IFN.Anifrolumab inhibits the activity of type I interferon and is used for the prevention and treatment of systemic lupus erythematosus (SLE).

IFN alpha-IFNAR-IN-1 is a nonpeptidic, low-molecular-weight inhibitor that disrupts the interaction between IFN-α and IFNAR, inhibiting MVA-induced IFN-α responses by BM-pDCs (IC50: 2-8 μM).

Anti-Mouse IFNAR1 Antibody (MAR1-5A3) is a neutralizing monoclonal antibody that specifically binds to IFNAR1, blocking its signaling both in vitro and in vivo. It is of the Mouse IgG1 kappa isotype, with a corresponding isotype control [1] [2].

Anti-IFNAR1 Antibody (Anifrolumab) is a humanized IgG1 kappa monoclonal antibody targeting the type I interferon receptor subunit 1 (IFNAR1). This product specifically binds to IFNAR1, blocking the interaction of all type I interferons (including all subtypes of IFN-alpha, IFN-beta, and IFN-omega) with the receptor complex. This inhibition blocks the activation of the downstream JAK/STAT signaling pathway, reduces the expression of interferon-stimulated genes (ISGs), and suppresses type I interferon-mediated immune responses.

Anti-Mouse IFNAR-1 Antibody (15A3.B) is a monoclonal antibody targeting mouse IFNAR-1. It can be used for immunology research involving interferon signaling.

2',3'-cGAMP sodium (2'-3'-cyclic GMP-AMP sodium) is a second messenger in cellular innate immunity, catalyzed by cGAMP synthase (cGAS) under DNA binding conditions. It binds to STING to form a dimer, inducing the production and expression of interferon-β and other cytokines.

EM 163 is a TIR-TIR interaction inhibitor, which is a TIR (Toll/interleukin-1 receptor) structural domain mimic of the MyD88 protein. EM 163 targets the TIR structural domain in the IL-1 receptor and blocks the interaction with MyD88. EM 163 inhibits the production of inflammatory cytokines in vivo caused by staphylococcal enterotoxin B (SEB). EM 163 protects mice from SEB shock-induced death. In rat hippocampal neurons in vitro, EM 163 blocked the activation of p38 and the inhibitory effect of IL-1β on chemically induced long-term potentiation (LTP)-triggered protein synthesis.

Feeblin(IRF5-IN-1) is a protein degradation inducer that specifically blocks pro-inflammatory signaling pathways associated with autoimmune diseases and can be used to study immune system disorders in the class of systemic lupus erythematosus.

Actarit (4-acetylaminophenylacetic acid) is an anti-inflammatory drug.

Royal Jelly Acid (Queen Bee Acid) is a major fatty acid found in royal jelly that promotes neuronal growth and protection and reduces anxiety. Royal Jelly Acid induces reactive oxygen species (ROS)-mediated apoptosis in A549 cells, improves non-alcoholic fatty liver disease by activating the AMPK-α signaling pathway, and reduces bone loss by inhibiting the NF-κB signaling pathway downstream of FFAR4. Royal Jelly Acid also exhibits inhibitory effects against various bacteria and fungi, including Aspergillus niger, mold, and Staphylococcus aureus. By targeting aspartyl β-hydroxylase and inhibiting chondrocyte senescence, Royal Jelly Acid exerts a preventive and therapeutic effect against osteoarthritis.

2'-Deoxy-2'-fluorouridine serves as an intermediate in the synthesis of antiviral agents targeting influenza viruses[1].

TNF/IFNγ-IN-1 (TGA) is a dual inhibitor of TNF and IFN-γ. TNF/IFNγ-IN-1 has potential antioxidant and anti-inflammatory activities for neurodegenerative diseases such as Alzheimer.